2019 IPO
Brickell Biotech Stock
Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.
Sign up today and learn more about Brickell Biotech Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Brickell Biotech Stock
Brickell Biotech, Inc., a Delaware corporation, is a development-stage pharmaceutical company focused on the acquisition, development and commercialization of innovative drug therapies for the treatment of skin diseases.
Funding History
| July 2010 | $6.2M |
|---|---|
| February 2013 | $7.0M |
| August 2014 | $2.2M |
| February 2015 | $10.0M |
Management
Co-Founder and President
Reginald Hardy
President and Chief Scientific Officer
Patricia Walker
Chief Financial Officer
Jerry Coombs
Vice President, New Product Development
Charles Betlach
Vice President, Product Development
Elizabeth Hussey
Vice President, Chemistry, Manufacturing, and Controls
John Koleng
Co-Founder and Vice President, Operations
Andrew Sklawer
Senior Vice President, Global Regulatory Affairs
Deepak Chadha
Press
Business Wire (press release) - Oct, 24 2017
Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with ...EquityZen Recognized As:
